Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma.
| Autor: | Noorduyn SG; AstraZeneca Canada Ltd, Mississauga, ON, Canada.; Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Johnston K; Broadstreet HEOR, Vancouver, BC, Canada.; Memorial University, St John's, NL, Canada., Osenenko K; Broadstreet HEOR, Vancouver, BC, Canada., Sriskandarajah N; AstraZeneca Canada Ltd, Mississauga, ON, Canada., Gendron A; Dept of Medicine, University of Montreal, Montreal, QC, Canada., Mbuagbaw L; Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ERJ open research [ERJ Open Res] 2021 Dec 06; Vol. 7 (4). Date of Electronic Publication: 2021 Dec 06 (Print Publication: 2021). |
| DOI: | 10.1183/23120541.00465-2021 |
| Abstrakt: | Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp. (Copyright ©The authors 2021.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|